title: I-123 iomazenil SPECT in patients with mental disorders.
abstract: The purpose of this study is visual evaluation of the distribution of I-123 iomazenil in the brains of patients with various types of mental disorder and to examine whether chronic administration of a clinical dose of benzodiazepine (BZ) affects the binding of I-123 iomazenil to BZ receptors (BZR). The subjects were 10 patients with mental disorders (3 males and 7 females) with a mean age of 26.8 yrs (range 19-39 yrs). Four of 10 patients were administered BZ for over 3 months and the other six were free of BZ for over one month. The SPECT images were obtained at 5-25 min (early) and 170-190 min (delayed), after the bolus i.v. injection of 167 MBq of I-123 iomazenil, with a triple-head gamma camera. The images were visually evaluated and the washout ratios of each region were calculated. In visual analysis, abnormalities were recognized in 5 patients on the delaye SPECT. The abnormalities were recognized more frequently in the superior frontal lobe. The washout ratio was higher in the BZ (+) patient group than in the BZ (-) patient group. I-123 iomazenil is useful, because the SPECT image with I-123 iomazenil reflects the distribution of BZR on the brain and provides the different information from that obtained with perfusion SPECT, X-ray CT or MRI. The rapid washout of I-123 iomazenil from the brains of BZ (+) patients suggests that chronic administration of a clinical dose of BZ affects the binding of I-123 iomazenil to BZR.
authors.affiliation: Department of Radiology, Faculty of Medicine, Kagoshima University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nakabeppu
authors.forename: M
authors.initials: M
authors.lastname: Nakajo
authors.forename: T
authors.initials: T
authors.lastname: Naruo
authors.forename: Y
authors.initials: Y
authors.lastname: Obo
authors.forename: S
authors.initials: S
authors.lastname: Nozoe
authors.forename: M
authors.initials: M
authors.lastname: Takigawa
authors.forename: S
authors.initials: S
authors.lastname: Tsuchimochi
authors.forename: A
authors.initials: A
authors.lastname: Tani
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005442:Flumazenil / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D001523:Mental Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D014151:Anti-Anxiety Agents; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D005442:Flumazenil; C063038:iomazenil